Top

Published in:

01-09-2012 | Original Article

Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review

Authors: David H. Henry, Corey J. Langer, R. Scott McKenzie, Catherine Tak Piech, Mekré Senbetta, Kathy L. Schulman, Edward J. Stepanski

Published in: Supportive Care in Cancer | Issue 9/2012

Abstract

Purpose

In July 2007, the Centers for Medicare and Medicaid Services (CMS) limited coverage of erythropoiesis-stimulating agents (ESAs) in cancer patients with chemotherapy-induced anemia (CIA) through a National Coverage Determination (NCD). The primary objective of this study was to compare transfusion rates in patients with CIA with lung, breast, or colorectal cancer before and after the NCD.

Methods

Adult Medicare patients with CIA treated at 49 community oncology clinics were selected from two time periods based on clinics' NCD implementation date. Chart data were abstracted for 12 weeks post-CIA episode start, defined as hemoglobin (Hb) level <11 g/dL while receiving chemotherapy or within 60 days of the last chemotherapy dose. Multivariate analyses were used to calculate the odds of transfusion and to assess the units of blood transfused, controlling for differences in demographics, clinical history, and chemotherapy.

Results

Eight hundred pre-NCD and 994 post-NCD patients from 49 sites were selected. Of the patients, 56% used ESAs post-NCD vs. 88% pre-NCD (p < 0.0001). The duration of ESA use decreased in the post-NCD (32.1 days) vs. pre-NCD (48.4 days, p < 0.0001) group. The post-NCD group reported significantly lower Hb levels, higher odds of receiving a transfusion (odds ratio: 1.41, 95% CI 1.05–1.89, p = 0.0238) and increased blood utilization of 53% (units transfused: OR 1.53, 95% CI 1.15–2.04, p = 0.0034).

Conclusions

Decreased frequency and duration of ESA administration were reported in the post-NCD vs. pre-NCD period. Findings were accompanied by a modest but statistically significant increase in transfusions and a decrease in Hb values.

Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616–1634PubMedCrossRef

Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293–2306PubMedCrossRef

Rodgers GM (2008) Managing patients with chemotherapy-induced anemia. Adv Stud Med 8:346–351

Feinberg B, Gilmore J, Gondesen T et al (2009) Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: results from a community oncology practice. Commun Oncol 6:257–261CrossRef

Shord SS, Auerbach M (2009) Treating chemotherapy-induced anemia following the revised labeling for ESAs. Commun Oncol 6:279–282CrossRef

Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 111:25–41PubMedCrossRef

Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960–5972PubMedCrossRef

Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260PubMedCrossRef

Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ (2008) Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care. Pharmacotherapy 28:1S–15SPubMedCrossRef

10.

Smith RE Jr, Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA (2008) Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26:1040–1050PubMedCrossRef

11.

Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122:394–403PubMedCrossRef

12.

Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non–small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027–1032PubMedCrossRef

13.

Overgaard J, Hoff CM, Hansen HS et al (2007) Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)—the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer Suppl 5:6LB

14.

Oncologic Drugs Advisory Committee briefing document: continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-02-FDA.pdf. Accessed 15 March 2010

15.

Background information for Oncologic Drugs Advisory Committee: safety of erythropoiesis-stimulating agents (ESAs) in oncology. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-01-01-Amgen.pdf. Accessed 15 March 2010

16.

Decision memo for erythropoiesis-stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). The use of erythropoiesis stimulating agents in cancer and related neoplastic conditions. Available at http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=203. Accessed 15 March 2010

17.

Information on erythropoiesis-stimulating agents (ESAs) epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Aranesp). Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109375.htm. Accessed 15 March 2010

18.

Naeim A, Glaspy J (2008) Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007. J Clin Oncol 26:20595CrossRef

19.

Burton T, Larholt K, Apgar E et al (2008) Pre- vs. post-National Coverage Determination (NCD) blood utilization and hemoglobin values among Medicare patients treated with erythropoiesis-stimulating agents (ESAs) for chemotherapy-induced anemia (CIA). In: American Society of Hematology, 50th Annual Meeting and Exposition, December 6–9, 2008, San Francisco, CA

20.

Centocor Ortho Biotech Products, L.P. (2010) Procrit® (epoetin alfa) full prescribing information. Centocor ortho Biotech Products, LP, Raritan, NJ

21.

Amgen Inc. (2010) Aranesp® (darbepoetin alfa) full prescribing information. Amgen Inc., Thousand Oaks, CA

22.

Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211–1220PubMedCrossRef

23.

Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606–2617PubMedCrossRef

24.

Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA (2009) Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 27:2838–2847PubMedCrossRef

25.

Hulnick SA, Hess G, Hill J et al (2009) Erythropoiesis stimulating agent (ESA) administration at Hb <10 g/dL for chemotherapy-induced anemia (CIA) following the National Coverage Decision (NCD). J Clin Oncol 27:e20627

26.

Shapira I, Raftopoulos H, Gralla RJ et al (2009) The impact of randomized trial results and altered regulatory policies on ESA use, transfusions, and thrombosis: a longitudinal analysis over a 3-year period of resource utilization data from a large comprehensive oncology program. J Clin Oncol 27:6611

Title: Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review
Authors: David H. Henry
Corey J. Langer
R. Scott McKenzie
Catherine Tak Piech
Mekré Senbetta
Kathy L. Schulman
Edward J. Stepanski
Publication date: 01-09-2012
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 9/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-011-1318-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2012

Drug-induced hallucinatory syndrome in a patient with breast cancer after paclitaxel infusion

Head-to-head comparisons of quality of life instruments for young adult survivors of childhood cancer

Using Screening for Distress, the Sixth Vital Sign, to advance patient care with assessment and targeted interventions

A new palliative care consultation team at the oncology department of a university hospital: an assessment of initial efficiency and effectiveness

What are the perceived needs and challenges of informal caregivers in home cancer palliative care? Qualitative data to construct a feasible psycho-educational intervention

Emergency department cancer unit and management of oncologic emergencies: experience in Asan Medical Center

Keynote webinar | Spotlight on antibody–drug conjugates in cancer